PMID- 24824028
OWN - NLM
STAT- MEDLINE
DCOM- 20140922
LR  - 20220408
IS  - 1532-8392 (Electronic)
IS  - 0046-8177 (Linking)
VI  - 45
IP  - 8
DP  - 2014 Aug
TI  - GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.
PG  - 1625-9
LID - S0046-8177(14)00144-0 [pii]
LID - 10.1016/j.humpath.2014.03.015 [doi]
AB  - The current available data on GATA-binding protein 3 (GATA3) expression in 
      sarcomatoid urothelial carcinoma are limited, especially in the non-tissue 
      microarray-based setting. In this study, we analyzed the expression of GATA3 in 
      sarcomatoid urothelial carcinoma of the bladder in cystectomy/cystoprostatectomy 
      specimens. A search was made through our surgical pathology and consultation 
      files for cystectomy/cystoprostatectomy specimens with a diagnosis of sarcomatoid 
      urothelial carcinoma. Only cases with available tissue blocks were selected. 
      Immunohistochemical staining for GATA3 was performed, and staining in 
      adjacent/overlying conventional urothelial carcinoma and/or benign urothelium was 
      also documented. Twenty-two cases were obtained. Of 22 cases, 16 (73%) of 
      sarcomatoid urothelial carcinoma were positive for GATA3. In the 7 (27%) of 22 
      cases that were negative for GATA3, it was observed that these cases were 
      predominantly composed either of pleomorphic undifferentiated sarcomatoid areas 
      or foci composed of extensive heterologous elements (chondroid, osteoid, or 
      rhabdoid). GATA3 staining was positive in the adjacent/overlying conventional 
      urothelial carcinoma and/or benign urothelium in all cases. This is one of the 
      largest studies to date analyzing the expression of GATA3 in sarcomatoid 
      urothelial carcinoma in cystectomy/cystoprostatectomy specimens. GATA3 is 
      expressed in most cases of sarcomatoid urothelial carcinoma. Negative expression 
      may, however, be observed in cases composed predominantly of pleomorphic 
      undifferentiated sarcomatoid areas or extensive heterologous elements. We 
      recommend including GATA3 in the panel of immunohistochemical stains for 
      sarcomatoid carcinomas of unknown origin, especially if a bladder primary is 
      being considered in the differential diagnosis.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Fatima, Nazneen
AU  - Fatima N
AD  - Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322.
FAU - Osunkoya, Adeboye O
AU  - Osunkoya AO
AD  - Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322; 
      Department of Urology, Emory University School of Medicine, Atlanta, GA 30322; 
      Emory Winship Cancer Institute, Atlanta, GA 30322. Electronic address: 
      adeboye.osunkoya@emory.edu.
LA  - eng
PT  - Journal Article
DEP - 20140413
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (GATA3 protein, human)
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Transitional Cell/*diagnosis/metabolism/pathology
MH  - GATA3 Transcription Factor/*metabolism
MH  - Humans
MH  - Urinary Bladder/*metabolism/pathology
MH  - Urinary Bladder Neoplasms/*diagnosis/metabolism/pathology
MH  - Urothelium/*metabolism/pathology
OTO - NOTNLM
OT  - Cystectomy
OT  - Cystoprostatectomy
OT  - GATA3
OT  - Sarcomatoid differentiation
OT  - Urothelial carcinoma
EDAT- 2014/05/16 06:00
MHDA- 2014/09/23 06:00
CRDT- 2014/05/15 06:00
PHST- 2014/02/11 00:00 [received]
PHST- 2014/03/21 00:00 [revised]
PHST- 2014/03/26 00:00 [accepted]
PHST- 2014/05/15 06:00 [entrez]
PHST- 2014/05/16 06:00 [pubmed]
PHST- 2014/09/23 06:00 [medline]
AID - S0046-8177(14)00144-0 [pii]
AID - 10.1016/j.humpath.2014.03.015 [doi]
PST - ppublish
SO  - Hum Pathol. 2014 Aug;45(8):1625-9. doi: 10.1016/j.humpath.2014.03.015. Epub 2014 
      Apr 13.